Free Trial
NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

Vincerx Pharma logo
$0.02 0.00 (0.00%)
As of 10/5/2026 09:30 AM Eastern

About Vincerx Pharma Stock (NASDAQ:VINC)

Advanced

Key Stats

Today's Range
$0.0150
▼
$0.0150
50-Day Range
$0.0002
▼
$0.0150
52-Week Range
$0.00
▼
$0.07
Volume
104 shs
Average Volume
4,664 shs
Market Capitalization
$78.51 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company’s research has centered on treatments designed to selectively affect cancer cells while limiting exposure to healthy tissue.

Vincerx’s pipeline has included enitociclib, formerly known as VIP152, an oral, selective cyclin-dependent kinase 9 (CDK9) inhibitor investigated for hematologic malignancies such as diffuse large B-cell lymphoma and acute myeloid leukemia. The company has also developed small-molecule drug conjugates, including VIP236, as part of its efforts to deliver anticancer agents directly to tumors.

Founded in 2019 and headquartered in Palo Alto, California, Vincerx has operated primarily as a U.S.-based drug development company, conducting research and clinical activities through collaborations and clinical studies. Its programs and corporate strategy have evolved as it has advanced and evaluated its oncology pipeline.

AI Generated. May Contain Errors.

Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VINC Stock News Headlines

Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.tc pixel
Vincerx Pharma, Inc. (VINC) - Yahoo Finance
See More Headlines

VINC Stock Analysis - Frequently Asked Questions

Vincerx Pharma's stock was trading at $0.0126 at the start of the year. Since then, VINC shares have increased by 19.0% and is now trading at $0.0150.

Vincerx Pharma, Inc. (NASDAQ:VINC) announced its quarterly earnings data on Thursday, August, 8th. The company reported ($1.00) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.40.

Vincerx Pharma's stock reverse split on Tuesday, January 28th 2025.The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and

Company Calendar

Last Earnings
8/08/2024
Today
10/06/2026
Next Earnings (Estimated)
11/10/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VINC
CIK
1796129
Fax
N/A
Employees
60
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$40.16 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-248.33%
Return on Assets
-132.73%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.17
Quick Ratio
2.17

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$10.50 per share
Price / Book
0.00

Miscellaneous

Outstanding Shares
5,234,000
Free Float
1,891,000
Market Cap
$78.51 thousand
Optionable
Not Optionable
Beta
1.46
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:VINC) was last updated on 10/6/2026 by MarketBeat.com Staff.
From Our Partners